IDM Pharma, Inc. today presented preliminary results from a Phase II UVIDEM (IDD-3) melanoma vaccine clinical trial (DC-MEL-202). The results showed that UVIDEM was well tolerated with evidence of efficacy and induction of immune response in patients with progressive metastatic melanoma.
The data were presented by Merrick I. Ross, M.D., Professor of Surgery, Chief, Melanoma Section, Department of Surgical Oncology at The University of Texas M. D. Anderson Cancer Center in Houston as an oral presentation titled "Clinical and immunological responses in patients with malignant melanoma treated with a dendritic cell-based vaccine. Preliminary report from a multi- institutional phase II clinical trial" (# 3004) at the 2007 American Society of Clinical Oncology (ASCO) 43rd annual meeting in Chicago.
Advertisement"We are in great need of new drugs to treat our patients with metastatic melanoma" said Dr. Ross. "The preliminary analysis of the phase II clinical trial with IDM Pharma's cancer vaccine, UVIDEM, suggests that several patients with advanced melanoma attained durable control of their disease after a treatment stimulating their own immune system cells. Additionally, the side effects experienced by our patients were minimal," he added.
PEurand and GSK Reach Development Milestone Manmohan Singh to Meet UN Chief, Discuss Climate Change M
You May Also Like